Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Lithium-Enhanced Exosomal Wnt10a Secretion Drives Osteogenes
2026-06-27
This study uncovers how lithium augments bone mesenchymal stem cell (BMSC) osteogenesis by promoting exosomal Wnt10a secretion and activating Wnt/β-catenin signaling. The mechanistic insights reveal Rab11a-mediated trafficking as a critical step, offering new translational avenues for improving bone regeneration strategies.
-
O6-Benzylguanine: Precision MGMT Inhibitor for Chemotherapy
2026-06-26
O6-Benzylguanine empowers researchers to overcome DNA repair-mediated chemotherapy resistance through targeted MGMT inhibition. This article spotlights hands-on workflows, protocol optimization, and actionable troubleshooting rooted in the latest translational findings.
-
Mycophenolic Acid: Dehydrogenase Inhibitor in Immune Assays
2026-06-26
Mycophenolic acid stands out as a research-grade dehydrogenase inhibitor enabling reproducible modulation of immune cell metabolism in whole-blood stimulation assays. By standardizing metabolic intervention protocols, researchers can precisely interrogate cytokine responses and immune regulation. APExBIO ensures high-quality supply for reliable, advanced immunometabolism exploration.
-
ONX-0914 (PR-957): Precision Immunoproteasome Inhibition in
2026-06-25
ONX-0914 (PR-957) delivers unmatched selectivity for immunoproteasome targeting, empowering researchers to dissect cytokine-driven pathology in autoimmune and inflammatory models. Explore advanced protocols and troubleshooting strategies that maximize its impact, with novel insights from recent studies illuminating new avenues for immune modulation.
-
Temozolomide: Small-Molecule Alkylating Agent for Glioma Mod
2026-06-25
Temozolomide empowers researchers to dissect DNA repair and chemotherapy resistance in glioma models, especially when ATRX status is a variable. This article delivers a stepwise workflow, advanced use-cases, and real-world troubleshooting, maximizing the unique properties of Temozolomide as a precision research tool.
-
Fasudil (HA-1077) HCl: Precision ROCK Inhibition for Cancer
2026-06-24
Explore how Fasudil (HA-1077) HCl, a selective ROCK inhibitor, enables advanced interrogation of cell proliferation, migration, and apoptosis in cancer and lens models. This article provides unique mechanistic insights and assay guidance, bridging oncology and ophthalmology research.
-
InstaBlue Protein Stain Solution: Fast, Sensitive Protein An
2026-06-23
InstaBlue Protein Stain Solution revolutionizes protein gel workflows with rapid, high-sensitivity staining—detecting as little as 5 ng of protein in minutes. Its mass spectrometry compatibility and non-toxic formulation make it ideal for advanced biomedical research, including studies on neuroprotection and oxidative stress.
-
TAI-1: Redefining Hec1 Inhibition for Genome Stability Resea
2026-06-23
Explore how TAI-1, a first-in-class Hec1 inhibitor, transforms the study of cancer genome stability and apoptotic cell death induction. This article uncovers unique mechanistic insights and advanced applications, providing new perspectives beyond workflow-focused guides.
-
ATRX Loss Sensitizes High-Grade Glioma to Multi-Targeted RTK
2026-06-22
The referenced study reveals that ATRX-deficient high-grade glioma cells are markedly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. These findings highlight the importance of ATRX mutational status as a biomarker for optimizing targeted therapy in aggressive gliomas.
-
CRTC-CREB Axis Senses Proteotoxic Stress via ROS/JNK in Dros
2026-06-22
The referenced study reveals that the CRTC-CREB transcriptional axis acts as a sensor for proteotoxic stress in Drosophila, linking proteasome inhibition to CREB activation via ROS/JNK signaling. These findings have significant implications for understanding protein aggregation diseases and for designing interventions that target proteostasis.
-
(S)-(+)-Dimethindene maleate: M2 Antagonist Use in Lab Resea
2026-06-21
(S)-(+)-Dimethindene maleate enables selective antagonism of the M2 muscarinic acetylcholine receptor and H1 histamine receptor, streamlining mechanistic studies in autonomic regulation, cardiovascular physiology, and respiratory system function. It is designed for controlled laboratory workflows and should not be used for diagnostic or therapeutic applications. Adherence to solubility and storage guidelines is essential for reproducibility.
-
Disulfiram as a Dopamine β-Hydroxylase Inhibitor in Cancer R
2026-06-20
Disulfiram stands out not only as a dopamine β-hydroxylase inhibitor but as a copper-dependent proteasome modulator, unlocking advanced workflows in cancer and inflammasome biology. This article delivers a protocol-rich, troubleshooting-focused guide to maximizing Disulfiram’s value in translational research, with actionable insights drawn from the latest mechanistic studies.
-
Resveratrol as a SIRT1 Activator: Optimizing Neuroprotection
2026-06-19
Resveratrol, a proven SIRT1 activator, delivers robust neuroprotection by modulating mitochondrial biogenesis and apoptosis in prion-challenged neuronal models. This article details advanced experimental workflows, evidence-based troubleshooting, and actionable protocol enhancements for researchers leveraging APExBIO's Resveratrol in translational neurodegeneration studies.
-
Doxorubicin Hydrochloride: Mechanism, Evidence & Research In
2026-06-19
Doxorubicin hydrochloride (Adriamycin HCl) is a benchmark anticancer agent and DNA topoisomerase II inhibitor, widely used in chemotherapy research. Its potent cytotoxicity, defined mechanisms of DNA intercalation, and well-characterized cardiotoxicity profile make it indispensable for modeling cancer biology and drug safety. This article details molecular actions, experimental benchmarks, and workflow integration for reproducible research.
-
Leptin (116-130), amide, mouse: Precision Tools for Targetin
2026-06-18
Explore Leptin (116-130), amide, mouse, an adipocyte-derived hormone fragment, as a precision research tool for dissecting energy homeostasis regulation and immune-metabolic crosstalk. This article provides advanced scientific insights and unique assay guidance beyond standard obesity research.